<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="328">
  <stage>Registered</stage>
  <submitdate>13/11/2002</submitdate>
  <approvaldate>13/11/2002</approvaldate>
  <nctid>NCT00049764</nctid>
  <trial_identification>
    <studytitle>Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis</studytitle>
    <scientifictitle>Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>F1K-MC-EVBP</secondaryid>
    <secondaryid>6716</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Poisoning</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Drotrecogin alfa (activated)
Treatment: drugs - Placebo

Experimental: 1 - 24 microgram/kg/hr for 96 hours (+ or - 1 hour)

Placebo Comparator: 2 - 0.9% sodium chloride


Treatment: drugs: Drotrecogin alfa (activated)


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>That drotrecogin alfa (activated) compared with placebo reduces severe-sepsis-induced organ dysfunction</outcome>
      <timepoint>3 Years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality data</outcome>
      <timepoint>3 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The effects of drotrecogin alfa (activated) on individual organ dysfunction</outcome>
      <timepoint>3 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amputation reduction (at or above the wrist, at or above the ankle, face, and genitals)in pediatric patients with Neisseria meningitidis</outcome>
      <timepoint>3 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Demonstrate that drotrecogin alfa (activated) has antithrombotic and anti-inflammatory properties.</outcome>
      <timepoint>3 Years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Suspected or proven acute infection.

          -  Abnormally high or low core body temperature

          -  Cardiovascular dysfunction which requires the use of vasoactive drugs (such as,
             dopamine, dobutamine, epinephrine) and is the result of severe sepsis.

          -  Respiratory dysfunction which requires the use of mechanical ventilation and is the
             result of severe sepsis.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients at increased risk of bleeding.

          -  Patients at high risk for an intracranial bleed.

          -  Patients who have undergone a bone marrow transplant.

          -  Patients with end-stage renal disease.

          -  Patients whose family or primary care physician is unwilling to allow transfusion of
             blood products.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>474</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,TAS</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Westmead</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Hobart</hospital>
    <postcode> - Westmead</postcode>
    <postcode> - Hobart</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago de Chile</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin-Bicetre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wurzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Benito Juarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hants</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purposes of this study are to determine:

        1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their
           condition more often or recover faster than children who do not receive drotrecogin alfa
           (activated).

        2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with
           severe sepsis.

        3. The side effects that might be associated with drotrecogin alfa (activated)
           administration to children with severe sepsis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00049764</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>